Plasmacytoma clinical trials
The registry lists 34 studies for Plasmacytoma across more than 10 countries. 6 are recruiting or about to start. 12 of them are mainly about Plasmacytoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-02.
Get an email when these change. Save the Plasmacytoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Mayo Clinic (2) · University of Arkansas (2) · Shenzhen Geno-Immune Medical Institute (2) · Memorial Sloan Kettering Cancer Center (2) · Alliance for Clinical Trials in Oncology (1) · Chinese PLA General Hospital (1) · Guenther Koehne (1) · Hebei Senlang Biotechnology Inc., Ltd. (1)
What is being tested here
Drugs under test in Plasmacytoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Chimeric Antigen Receptor T-cells | 1 | 0 | 1 |
| Fluorine F 18 FAPI-74 | 1 | 0 | 1 |
| Cyclophosphamide | 1 | 0 | 1 |
| Fludarabine | 1 | 0 | 1 |
| Dexamethasone | 0 | 1 | 4 |
| Lenalidomide | 0 | 1 | 2 |
| Pomalidomide | 0 | 0 | 2 |
| Ixazomib | 0 | 0 | 2 |
| Filanesib | 0 | 0 | 2 |
| Cc-486 | 0 | 0 | 1 |
Drug classes tested here Antimetabolites 1 open · Proteasome inhibitors 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
- Nov 2026A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma · Memorial Sloan Kettering Cancer Center
- Dec 2026Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration · Institute of Hematology & Blood Diseases Hospital, China
Who these studies take
Of the 3 Plasmacytoma studies recruiting now, 1 (33%) set no upper age limit and 1 (33%) stop at 75 or younger. 1 (33%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 3 (100%) | 3 (100%) |
| 40 | 3 (100%) | 3 (100%) |
| 50 | 3 (100%) | 3 (100%) |
| 65 | 3 (100%) | 3 (100%) |
| 75 | 3 (100%) | 3 (100%) |
| 85 | 1 (33%) | 1 (33%) |
Across all 34 studies, recruiting or not: 15% stop at 75 or younger and 3% at 65; 9% take children; 0% are for women only and 0% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 34 of 34. search them.
- Engineered Dendritic Cell Vaccines for Multiple MyelomaNot yet recruitingNCT06435910Phase 11 country
- Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or PlasmacytomaNot yet recruitingNCT06429150Phase 1/21 country
- The Indiana Myeloma RegistryRecruitingNCT036164831 country
- FAPI PET Imaging - An Exploratory StudyNot yet recruitingNCT07705074Phase 1/21 country
- Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow InfiltrationRecruitingNCT07115667Phase 21 country
- Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell TumorsRecruitingNCT04665076Not applicable1 country
- Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of BoneTerminatedNCT02516423Phase 31 country
- Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line SettingCompletedNCT01946477Phase 24 countries
- Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple MyelomaTerminatedNCT03031730Phase 11 country
- A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With PlasmacytomaActive, not recruitingNCT04174196Phase 21 country
- Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02136134Phase 315 countries
- Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple MyelomaCompletedNCT02506959Phase 21 country
- Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS SyndromeCompletedNCT02921893Early Phase 11 country
- T-cell Receptor α/β Depleted Donor Lymphocyte InfusionTerminatedNCT05350163Phase 11 country
- Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic CancerCompletedNCT02184533Phase 11 country
- The Value of Systematic Biopsies During Vertebroplasty for the Treatment of Osteoporotic Vertebral FracturesCompletedNCT061535761 country
- Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT02547662Phase 21 country
- Trial of Immunomodulatory Therapy in High Risk Solitary Bone PlasmacytomaActive, not recruitingNCT02544308Phase 31 country
- Stereotactic Body Radiotherapy for the Treatment of Solitary Bone PlasmacytomaTerminatedNCT03312868Phase 21 country
- Phase I/II Study of hLL1 in Multiple MyelomaCompletedNCT00421525Phase 1/21 country
- A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00821249Phase 1/21 country
- A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01248923Phase 11 country
- Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple MyelomaStatus unknownNCT04162119Phase 21 country
- Daratumumab With DCEP for Multiple Myeloma With PlasmacytomaStatus unknownNCT04065308Phase 21 country
- A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone PlasmacytomaWithdrawnNCT03196401Phase 11 country
- Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and DexamethasoneCompletedNCT009111051 country
- S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary PlasmacytomaTerminatedNCT00109889Phase 21 country
- Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant TherapyStatus unknownNCT023033531 country
- CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary PlasmacytomaStatus unknownNCT02336386Phase 31 country
- UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00569868Not applicable1 country
- Study of CX-4945 in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT01199718Phase 11 country
- An Open Protocol for the Compassionate Use of ThalidomideCompletedNCT00081757Phase 1/21 country
- Dendritic Cells(DC)-Based Id Vaccination in Stage-I MyelomaCompletedNCT00988312Phase 11 country
- Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple MyelomaCompletedNCT00781170Phase 2